New Delhi, 5th December, 2024: Meril Life Sciences, a leading global med-tech company specializing in cardiovascular and structural heart solutions, marked a significant milestone with the launch of its Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 (National Congress of the Italian Society of Interventional Cardiology) and PCR London Valves 2024. These esteemed scientific events provided an ideal platform for Meril to showcase its commitment to advancing structural heart care.
The Myval THV series, known for its innovative contributions to transcatheter aortic valve replacement (TAVR) procedures, continues to set new benchmarks with the Myval Octapro THV. This latest iteration introduces low frame foreshortening, enhancing operator control and enabling precise deployment for improved procedural predictability. Additionally, its comprehensive size matrix, which includes conventional, intermediate, and extra-large valve sizes, ensures optimal valve selection tailored to diverse patient anatomies.
Dr. Ashok Seth, Chairman of Fortis Escorts Heart Institute and Fortis Healthcare Medical council, Delhi
Congratulations to Meril Life Sciences on the launch of the novel MyvalOctapro. We are proud Meril has been consistently innovating to set fresh benchmarks in Transcatheter structural therapies as well as proving them to be safe and effective through well conducted perspective randomised studies. Octapro THV is next-generation balloon expandable valve minimal foreshortening to enable precise deployment and commisural alignment Furthermore, the nine valve sizes (which includes intermediate sizing and extra-large size) enables accurate and appropriate fit to patient’s anatomy. In fact, approx. 50% of Myval THV series implants are intermediate-sized devices, which gives operators a wider options to all possible annular anatomies
Dr. Rajneesh Kapoor, Chairman, Interventional Cardiology, Medanta the Medicity, Gurugram, Haryana
We have a busy TAVI practice, and all my patients with MyvalOctapro have been successfully treated and continue to do well. MyvalOctapro THV is a landmark achievement in the evolution of transcatheter heart valve technology. Meril’s commitment to addressing unmet clinical needs and delivering precision-driven solutions continues to inspire the global medical community. Kudos to the entire team at Meril for their groundbreaking work!
Speaking on this achievement, Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, stated: “The positive reception of the Myval Octapro THV at these global platforms underscores our commitment to delivering cutting-edge solutions for severe aortic stenosis. We are proud to collaborate with clinicians worldwide in advancing TAVR technology and improving patient outcomes through innovation.”
At PCR London Valves 2024, Meril presented key findings from the LANDMARK trial subset analysis and comparative studies, further establishing the safety and efficacy of the Myval Transcatheter Heart Valve (THV) series. Published in EuroIntervention Journal, the findings confirmed the Myval THV’s non-inferiority to both Sapien and Evolut valve series at 30 days post-implantation, solidifying its position as a reliable solution for structural heart interventions.
The results highlighted comparable composite safety and effectiveness outcomes between Myval and Sapien (24.7% vs. 24.1%), with Myval demonstrating a lower rate of permanent pacemaker implantation (15.0% vs. 17.3%) and superior hemodynamic performance. Similarly, the Myval THV series performed on par with Evolut in composite endpoints (24.7% vs. 30%), while showing advantages in reducing pacemaker implantation rates and moderate/severe valve regurgitation. Effective orifice areas were also comparable between 26 and 29 mm of Myval THV series and Evolut THV series, underscoring its strong performance in key clinical measures.
The conference also featured the unveiling of the COMPARE-TAVI trial results. Presented by Prof. Henrik Nissen on behalf of the COMPARE-TAVI investigators, this first-of-its-kind randomized controlled trial directly compared the Myval THV series with the Sapien THV series in a real-world, all-comers population.
Key Findings from the COMPARE-TAVI Trial:
Meril acknowledges the invaluable contributions of clinicians, partners, and patients in achieving this milestone. With the launch of the Myval Octapro THV, Meril continues its mission of improving lives through pioneering structural heart care solutions.
About Meril Life Sciences:
Meril is a leading global medical device manufacturing company based in India that has been pivotal in establishing India as a leader in the global medical devices industry. The company’s strong focus on research and development (R&D) and commitment to quality have allowed it to offer cutting-edge medtech solutions in more than 135 countries. Additionally, Meril has a large presence in India with wholly-owned subsidiaries in the USA, UK, Europe, Middle East, Africa, Brazil, South America, Australia & Asia.
With its strong commitment to innovation and quality, Meril has transformed healthcare in India and created significant footprints across the globe. Through global partnerships and the use of advanced technology, the company prioritizes quality and adherence to international standards, fostering a thriving R&D environment. Meril’s efforts have effectively established India as a center for medical device innovation and production.
Image Name: Old Hollywood Glamour at the Golden Globes Image Credit: Vogue Old Hollywood glitz…
Image Name: New Sleep Therapy for Insomnia Image Credit: Vogue A lot of people cannot…
Image Name: LG's Projector-Speaker-Mood Lamp Image Credit: ZNDET Change goes on in the technological world,…
Image Name: Best Time for Coffee Image Credit: India Today More than just an everyday…
Image Name: Fashioning a Better Future for 2025 Image Credit: Fashion United It always reflects…
Image Name: Rolls-Royce Factory Expansion Image Credit: Rolls Royce Press Club Rolls-Royce is one of…